AMERISOURCEBERGEN Stock Price, News & Analysis

abc NYSE

Company Description

Cencora, Inc. (NYSE: COR), formerly known as AmerisourceBergen Corporation, is a leading global pharmaceutical solutions organization dedicated to improving the lives of people and animals worldwide. With a unified identity and vision under the new name, Cencora connects pharmaceutical innovators, care providers, pharmacies, and patients to ensure the seamless and reliable delivery of vital therapies and healthcare products.

Headquartered in Conshohocken, Pennsylvania, Cencora boasts a comprehensive portfolio of services across the pharmaceutical value chain. The company is renowned for its robust pharmaceutical distribution network, specialty logistics, and biopharma services, ensuring medications reach their destinations efficiently and safely. Cencora's extensive reach is evidenced by its operations in over 50 countries, supported by a team of more than 46,000 dedicated employees.

Cencora's commitment to innovation is further highlighted through initiatives like Cencora Ventures, the company's corporate venture fund dedicated to fostering healthcare advancements. Additionally, the Cencora Impact Foundation underscores the company's dedication to social responsibility, with a recent $5 million donation to support global healthcare initiatives, including a significant grant to UNICEF Health Fund.

Financially, Cencora is a powerhouse with more than $200 billion in annual revenue, ranking #11 on the Fortune 500 and #24 on the Global Fortune 500. The company's strategic investments, such as the acquisition of OneOncology and PharmaLex, showcase its focus on expanding its specialty and global commercialization services. Cencora's recent name change reflects its bold vision and purpose-driven approach to creating healthier futures, unifying its global presence under one cohesive brand.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

24.95 %

Performance 1 year

$36.1B

Market Cap

215.9M

Shares outstanding

Latest News

View All

October 2, 2023

0.00%

Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release

earnings

August 30, 2023

0.00%

AmerisourceBergen becomes Cencora, in alignment with the company’s growing global footprint and central role in pharmaceutical access and care

August 15, 2023

1.17%

AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors

management

August 3, 2023

0.00%

Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $1.85 Billion of Initial Proceeds

August 3, 2023

3.15%

AmerisourceBergen Announces Registered Public Offering of Common Shares and Common Share Repurchase

buyback offering

August 2, 2023

1.23%

AmerisourceBergen Reports Fiscal 2023 Third Quarter Results

earnings

SEC Filings

View All

No SEC filings available for AMERISOURCEBERGEN.

Financial Highlights

$66,947,043,000

Revenue (TTM)

$479,213,000

Net Income (TTM)

$2.35

Diluted EPS (TTM)

$744,935,000

Operating Cash Flow

0.72%

Net Profit Margin

1.00%

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the market cap of AMERISOURCEBERGEN (abc)?

The market cap of AMERISOURCEBERGEN (abc) is approximately 36.1B.

What is the revenue (TTM) of AMERISOURCEBERGEN (abc) stock?

The trailing twelve months (TTM) revenue of AMERISOURCEBERGEN (abc) is $66,947,043,000.

What is the net income of AMERISOURCEBERGEN (abc)?

The trailing twelve months (TTM) net income of AMERISOURCEBERGEN (abc) is $479,213,000.

What is the earnings per share (EPS) of AMERISOURCEBERGEN (abc)?

The diluted earnings per share (EPS) of AMERISOURCEBERGEN (abc) is $2.35 on a trailing twelve months (TTM) basis.

What is the operating cash flow of AMERISOURCEBERGEN (abc)?

The operating cash flow of AMERISOURCEBERGEN (abc) is $744,935,000.

What is the profit margin of AMERISOURCEBERGEN (abc)?

The net profit margin of AMERISOURCEBERGEN (abc) is 0.72%.

What is the operating margin of AMERISOURCEBERGEN (abc)?

The operating profit margin of AMERISOURCEBERGEN (abc) is 1.00%.

What is the gross margin of AMERISOURCEBERGEN (abc)?

The gross profit margin of AMERISOURCEBERGEN (abc) is 3.38%.

What is the current ratio of AMERISOURCEBERGEN (abc)?

The current ratio of AMERISOURCEBERGEN (abc) is 0.88, indicating the company's ability to pay short-term obligations.

What is the gross profit of AMERISOURCEBERGEN (abc)?

The gross profit of AMERISOURCEBERGEN (abc) is $2,264,646,000 on a trailing twelve months (TTM) basis.

What is the operating income of AMERISOURCEBERGEN (abc)?

The operating income of AMERISOURCEBERGEN (abc) is $670,128,000.

What is Cencora, Inc.?

Cencora, Inc., formerly AmerisourceBergen Corporation, is a global pharmaceutical solutions organization focused on improving the lives of people and animals through secure, reliable delivery of healthcare products and services.

Why did AmerisourceBergen change its name to Cencora?

The name change to Cencora reflects the company's unified global presence and its commitment to creating healthier futures with a purpose-driven approach. It represents the company's vision and strategic growth in the healthcare sector.

What services does Cencora provide?

Cencora offers a wide range of services, including pharmaceutical distribution, specialty logistics, biopharma services, and market access solutions, ensuring that medications and healthcare products reach their destinations efficiently and safely.

What recent strategic investments has Cencora made?

Cencora has recently acquired OneOncology, a network of leading oncology practices, and PharmaLex, a regulatory consulting firm. These investments enhance Cencora's specialty services and global commercialization capabilities.

How does Cencora contribute to social responsibility?

Cencora is committed to social responsibility through initiatives like the Cencora Impact Foundation, which recently announced a $5 million donation to support global healthcare efforts, including a significant grant to the UNICEF Health Fund.

What is Cencora Ventures?

Cencora Ventures, formerly known as AB Health Ventures, is Cencora's corporate venture fund dedicated to advancing healthcare innovation. The fund supports startups and initiatives that align with Cencora's mission to improve healthcare access globally.

How large is Cencora's workforce?

Cencora employs over 46,000 team members worldwide, working across various segments of the pharmaceutical value chain to ensure the delivery of critical healthcare products and services.

What is Cencora's financial standing?

Cencora is a financial leader in the healthcare industry, with more than $200 billion in annual revenue. The company is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500.

When did Cencora begin trading under the new ticker symbol?

Cencora began trading under the new ticker symbol 'COR' on the New York Stock Exchange on August 30, 2023.

What is the purpose of the Cencora Healthier Futures Grant Program?

The Cencora Healthier Futures Grant Program, launched by the Cencora Impact Foundation, aims to support healthcare innovation and access for underserved populations. The inaugural grant of $500,000 was awarded to the UNICEF Health Fund.